Avenue Therapeutics (NASDAQ: ATXI)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-14 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-30 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Avenue Therapeutics (NASDAQ: ATXI) through any online brokerage.
Other companies in Avenue Therapeutics’s space includes: Dermata Therapeutics (NASDAQ:DRMA), Pulmatrix (NASDAQ:PULM), Baudax Bio (NASDAQ:BXRX), Aytu BioPharma (NASDAQ:AYTU) and Kiora Pharmaceuticals (NASDAQ:KPRX).
The latest price target for Avenue Therapeutics (NASDAQ: ATXI) was reported by HC Wainwright & Co. on Tuesday, May 12, 2020. The analyst firm set a price target for 13.00 expecting ATXI to rise to within 12 months (a possible 4303.79% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Avenue Therapeutics (NASDAQ: ATXI) is $0.2952 last updated August 16, 2022, 8:00 PM UTC.
There are no upcoming dividends for Avenue Therapeutics.
Avenue Therapeutics’s Q3 earnings are confirmed for Monday, November 14, 2022.
There is no upcoming split for Avenue Therapeutics.
Avenue Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.